← Back to Clinical Trials
Recruiting NCT06794255

Exploratory Study on the Role of Vitamin C in Promoting Health in Middle-Aged and Elderly Adults

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Ageing
Sponsor Peking University Third Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 400
Sex ALL
Min Age 18 Years
Max Age 70 Years
Start Date 2025-04-02
Completion 2026-01-30
Interventions
Vitamin CPlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this clinical trial is to understand whether oral vitamin C can help delay the aging of middle-aged and elderly individuals, search for sensitive biomarkers of human aging, and provide new paradigms and scientific guidance for aging intervention with small molecule drugs. The main questions it aims to answer are as follows: * Can oral vitamin C effectively improve the aging-related indicators? * What is the safety of participants when taking vitamin C supplements? Researchers will compare vitamin C with a placebo to observe whether vitamin C is effective in intervening in the aging of middle-aged and elderly individuals. Participants need to: * Take 2 tablets (250mg/tablet) of vitamin C or placebo after breakfast and dinner every day for 12 consecutive months; * Go to the designated place for a face-to-face follow-up every 6 months and receive a telephone follow-up every 2 months, and pick up subsequent drugs during the follow-up; * Honestly inform the medication situation during each follow-up; * Report any discomfort or adverse reactions that occur during the treatment process to the researchers; * Fill in a questionnaire about their own health status during each follow-up; * After 6 months and 12 months of intervention, conduct a comprehensive health examination as required, including blood tests and other items.

Eligibility Criteria

Inclusion Criteria: * Age: 55-65 years (for the experimental and control groups) or 18-70 years (for the baseline control group assessing aging changes). * Health Status: Deemed to be in good health based on medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring. * Weight: BMI within the range of 18.5-28 kg/m². * Informed Consent: Capable of signing the informed consent form and complying with the requirements and restrictions outlined in the study protocol. Exclusion Criteria: * Disease Status:Uncontrolled medical conditions or any disease that, in the investigator's opinion, may pose an inappropriate risk or contraindication or interfere with the study's objectives, conduct, or evaluation.Severe chronic or acute diseases (e.g., cancer, heart failure, renal insufficiency, COPD, diabetes, active liver disease, metabolic acidosis, poorly controlled hypertension, epilepsy, recent cardiovascular events, inflammatory bowel disease, neu

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}